FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387208238> ?p ?o ?g. }

• W4387208238 endingPage "S28" @default.
• W4387208238 startingPage "S27" @default.
• W4387208238 abstract "To report the efficacy and toxicity outcomes of a prospective phase II trial of primary tumor SBRT followed by conventional chemoradiation to the lymph nodes and adjuvant immunotherapy in patients (pts) with unresectable LA NSCLC.Eligible pts included stage II-III LA NSCLC with peripheral primary tumors ≤ 7cm or centrally based tumors that had at least 2 cm separation from involved nodal disease. Pts received SBRT to the primary tumor (50-54 Gy in 3-5 fractions) followed by standard radiation to 60 Gy in 30 fractions to the involved lymph nodes with concurrent platinum doublet chemotherapy. The trial was amended to allow pts without disease progression after chemoradiation to receive adjuvant durvalumab per the PACIFIC trial. The primary endpoint was 1 year progression free survival (PFS), evaluated as a binary variable. Frequencies and proportions were used for reporting this primary endpoint, in addition to adverse events and patterns of failure. Median PFS and OS were estimated using Kaplan Meier methods.Safety and efficacy is reported on the first 50 pts enrolled in the trial with a median follow-up of 24 months (mos) (range, 1-54 mos). Pts were primarily stage IIIA (60%) or stage IIIB (34%), with 6% of pts stage IIB. Overall grade 3 or higher toxicity related to SBRT and/or mediastinal radiation was 8% with two pts (4%) developing grade 3 pneumonitis and one pt having a grade 5 lung infection possibly related to radiation. Overall grade 2 pneumonitis related to SBRT or mediastinal radiation was 20%. Only one pt (2%) developed grade 3 esophagitis. No late cardiac events have been observed. The one-year PFS for all pts was 62% with a median PFS of 26.3 mos and median overall survival of 40.8 mos. Of the 50 pts enrolled, 37 received at least one dose of adjuvant durvalumab. The one-year PFS for pts who received at least one dose of durvalumab was 70.3% with a median PFS not yet reached in this group (median follow-up 24 mos). Patterns of failure were mostly distant with 26% of pts experiencing distant failure, 6% regional, and 2% distant and regional. There was only one local failure (2%) after SBRT in all 50 pts.SBRT to the primary tumor followed by conventional chemoradiation to the involved lymph nodes and adjuvant immunotherapy was well tolerated and showed improved 1-year PFS compared to prior conventional chemoradiation trials for locally advanced NSCLC. The results of this trial will be further evaluated in a randomized phase III study, NRG LU-008. Pts will receive either conventional chemoradiation vs. SBRT to the primary tumor followed by chemoradiation to the involved lymph nodes followed by consolidative immunotherapy to evaluate the possibility of utilization of SBRT as a new standard of care for LA NSCLC." @default.
• W4387208238 created "2023-09-30" @default.
• W4387208238 creator A5002225991 @default.
• W4387208238 creator A5010741371 @default.
• W4387208238 creator A5023679911 @default.
• W4387208238 creator A5024671529 @default.
• W4387208238 creator A5026408052 @default.
• W4387208238 creator A5032979083 @default.
• W4387208238 creator A5039386937 @default.
• W4387208238 creator A5050864316 @default.
• W4387208238 creator A5054480789 @default.
• W4387208238 creator A5059850025 @default.
• W4387208238 creator A5061377808 @default.
• W4387208238 creator A5067536094 @default.
• W4387208238 creator A5077220174 @default.
• W4387208238 creator A5080870057 @default.
• W4387208238 creator A5089940903 @default.
• W4387208238 creator A5092083646 @default.
• W4387208238 date "2023-10-01" @default.
• W4387208238 modified "2023-10-17" @default.
• W4387208238 title "Prospective Phase II Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy (SBRT) Followed By Concurrent Mediastinal Chemoradiation and Adjuvant Immunotherapy for Locally-Advanced Non-Small Cell Lung Cancer (LA NSCLC)" @default.
• W4387208238 doi "https://doi.org/10.1016/j.ijrobp.2023.06.287" @default.
• W4387208238 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37784465" @default.
• W4387208238 hasPublicationYear "2023" @default.
• W4387208238 type Work @default.
• W4387208238 citedByCount "0" @default.
• W4387208238 crossrefType "journal-article" @default.
• W4387208238 hasAuthorship W4387208238A5002225991 @default.
• W4387208238 hasAuthorship W4387208238A5010741371 @default.
• W4387208238 hasAuthorship W4387208238A5023679911 @default.
• W4387208238 hasAuthorship W4387208238A5024671529 @default.
• W4387208238 hasAuthorship W4387208238A5026408052 @default.
• W4387208238 hasAuthorship W4387208238A5032979083 @default.
• W4387208238 hasAuthorship W4387208238A5039386937 @default.
• W4387208238 hasAuthorship W4387208238A5050864316 @default.
• W4387208238 hasAuthorship W4387208238A5054480789 @default.
• W4387208238 hasAuthorship W4387208238A5059850025 @default.
• W4387208238 hasAuthorship W4387208238A5061377808 @default.
• W4387208238 hasAuthorship W4387208238A5067536094 @default.
• W4387208238 hasAuthorship W4387208238A5077220174 @default.
• W4387208238 hasAuthorship W4387208238A5080870057 @default.
• W4387208238 hasAuthorship W4387208238A5089940903 @default.
• W4387208238 hasAuthorship W4387208238A5092083646 @default.
• W4387208238 hasConcept C126322002 @default.
• W4387208238 hasConcept C126838900 @default.
• W4387208238 hasConcept C143998085 @default.
• W4387208238 hasConcept C203092338 @default.
• W4387208238 hasConcept C2776256026 @default.
• W4387208238 hasConcept C2776694085 @default.
• W4387208238 hasConcept C2777714996 @default.
• W4387208238 hasConcept C2779524853 @default.
• W4387208238 hasConcept C2779984678 @default.
• W4387208238 hasConcept C31760486 @default.
• W4387208238 hasConcept C509974204 @default.
• W4387208238 hasConcept C535046627 @default.
• W4387208238 hasConcept C71924100 @default.
• W4387208238 hasConceptScore W4387208238C126322002 @default.
• W4387208238 hasConceptScore W4387208238C126838900 @default.
• W4387208238 hasConceptScore W4387208238C143998085 @default.
• W4387208238 hasConceptScore W4387208238C203092338 @default.
• W4387208238 hasConceptScore W4387208238C2776256026 @default.
• W4387208238 hasConceptScore W4387208238C2776694085 @default.
• W4387208238 hasConceptScore W4387208238C2777714996 @default.
• W4387208238 hasConceptScore W4387208238C2779524853 @default.
• W4387208238 hasConceptScore W4387208238C2779984678 @default.
• W4387208238 hasConceptScore W4387208238C31760486 @default.
• W4387208238 hasConceptScore W4387208238C509974204 @default.
• W4387208238 hasConceptScore W4387208238C535046627 @default.
• W4387208238 hasConceptScore W4387208238C71924100 @default.
• W4387208238 hasIssue "2" @default.
• W4387208238 hasLocation W43872082381 @default.
• W4387208238 hasLocation W43872082382 @default.
• W4387208238 hasOpenAccess W4387208238 @default.
• W4387208238 hasPrimaryLocation W43872082381 @default.
• W4387208238 hasRelatedWork W1975025425 @default.
• W4387208238 hasRelatedWork W2055244776 @default.
• W4387208238 hasRelatedWork W2348529436 @default.
• W4387208238 hasRelatedWork W2357406576 @default.
• W4387208238 hasRelatedWork W2404042595 @default.
• W4387208238 hasRelatedWork W2407189953 @default.
• W4387208238 hasRelatedWork W2413020017 @default.
• W4387208238 hasRelatedWork W3177224496 @default.
• W4387208238 hasRelatedWork W4382279650 @default.
• W4387208238 hasRelatedWork W1899415052 @default.
• W4387208238 hasVolume "117" @default.
• W4387208238 isParatext "false" @default.
• W4387208238 isRetracted "false" @default.
• W4387208238 workType "article" @default.